Plus TherapeuticsPSTV
Market Cap: $9.43M
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 20
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
451% more capital invested
Capital invested by funds: $182K [Q1] → $1M (+$820K) [Q2]
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 [Q1] → 12 (+2) [Q2]
9.6% more ownership
Funds ownership: 2.36% [Q1] → 11.96% (+9.6%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Ascendiant Capital Edward Woo 39% 1-year accuracy 14 / 36 met price target | 1,150%upside $20 | Buy Maintained | 3 Sept 2024 |
HC Wainwright & Co. Sean Lee 50% 1-year accuracy 10 / 20 met price target | 400%upside $8 | Buy Reiterated | 16 Aug 2024 |